Secure supply chain with PlexZyme^® Technology

Effective COVID-19 management is dependent on reliable and frequent testing. Disruptions in global manufacturing supply chains continue to limit availability of laboratory diagnostic kits, impacting local testing strategies.

SpeeDx utilises PlexZyme^® technology, de-coupling the detection probe from the primer sequence to produce universal probes. These probes are used across our entire product portfolio, enabling production and stockpiling of the probes well in excess of ‘market demand’ to negate any impact from supply chain constraints. This enables us to manufacture and readily ship kits in high volumes at all times – ensuring no interruptions to your daily laboratory testing.  Learn more.

Confident SARS-CoV-2 testing

SARS-CoV-2 continues to mutate, giving rise to variants potentially impacting diagnostic testing and reporting. Reliable and accurate diagnostics are required by laboratories to save time, resources, and to have confidence in the data reported.

SpeeDx routinely monitor the performance of our PlexPCR^® SARS-CoV-2 assay against emerging variants to ensure your laboratory can continue to report patient test data with no hesitation. Learn more.

What is Resistance Guided Therapy?

Resistance Guided Therapy (RGT) uses advances in diagnostic technology to help clinicians choose the best targeted therapy for individual patients based on the resistance status of their infection.

• RGT uses tests that detect the infecting organism and genetic markers linked to antibiotic susceptibility or infection
• RGT can replace empiric treatment models by providing additional information at the time of diagnosis to guide appropriate treatment decisions

Why is Resistance Guided Therapy important?

Strategies for controlling many STIs are dependent on the availability of inexpensive yet highly effective antibiotics. As antimicrobial resistance rates rise in these infections it is even more important to use our limited antibiotics more wisely.

Guidelines for management of STIs caused by Mycoplasma genitalium and Neisseria gonorrhoeae increasingly recommend RGT to help:

• improve likelihood of effective patient treatment
• reduce re-admission and healthcare costs
• minimise the spread of antibiotic resistant infections
• maintain the efficacy of antibiotic treatment (antibiotic stewardship)

Declining cure rates when employing detection-only practices for M. genitalium addressed with implementation of RGT, increasing cure rates for macrolide susceptible populations to 95% and total population cure rate over 92%.¹